

The FDA validates Doctomatic as a healthcare management solution

Doctomatic is a tool to support healthcare professionals in making data-based clinical decisions.

NY, UNITED STATES, February 25, 2025 /EINPresswire.com/ -- Doctomatic, the Barcelona-based startup that transforms images from medical devices into data using AI, has received official communication from the US Food and Drug Administration (FDA), validating its technology as a complementary solution in the management of patient health, including the monitoring and management of non-communicable diseases (NCDs). (FDA), which validates its technology as a complementary solution in the management of patient health, including the monitoring and management of non-communicable diseases (NCDs).



Patent pending proprietary algorithm which allows a universal protocol to capture the data of all devices

“

This is a big step for Doctomatic, as it validates our mission to offer accessible solutions for patient care. It allows us to continue our expansion in the US with complete security and transparency”

*Carmen Pauline Rios Benton,
CEO & Co-Founder*

The FDA has determined that Doctomatic does not require registration, pre-market review, or compliance with post-market or quality system regulations. This decision reinforces confidence in the safety and effectiveness of the API platform.

‘This confirmation from the FDA is a big step for Doctomatic, as it validates our mission to offer innovative and accessible solutions for remote patient monitoring. It allows us to continue our expansion in the US with complete security and transparency,’ says Carmen Pauline Rios Benton, CEO of Doctomatic.

The company reaffirms its commitment to improving digital healthcare, facilitating access to remote monitoring and supporting healthcare professionals in making data-driven clinical

decisions. With a special focus on non-communicable diseases, Doctomatic enables doctors and patients to manage chronic conditions such as diabetes, hypertension and cardiovascular disease in a more efficient and personalised way.

Founded in 2021, Doctomatic is supported by investors (ESC Venture Capital, Ship2B Ventures) and business angels (Col·legi d'Economistes BAN). Its clients include Clariane, Europe 's leading geriatrics group, and Hospital Sant Joan de Déu, among others. Doctomatic is also currently a member of the Digital Health and Data Strategic Committee of the WHO.

For more information, please visit: www.doctomatic.com/en/

Press contact:

Carmen Rios

carmen@doctomatic.com

+34 615 323 649

Carmen Pauline Rios Benton

Doctomatic

+34 615 32 36 49

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/788759782>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.